CL2008002114A1 - Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos-3-sustituidos; composicion farmaceutica; y uso del compuesto para el tratamiento de un trastorno mental propagado por estres, enfermedad de parkinson, esquizofrenia, trastorno de deficit de atencion, trastorno obsesivo compulsivo, psicosis, entre otras. - Google Patents

Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos-3-sustituidos; composicion farmaceutica; y uso del compuesto para el tratamiento de un trastorno mental propagado por estres, enfermedad de parkinson, esquizofrenia, trastorno de deficit de atencion, trastorno obsesivo compulsivo, psicosis, entre otras.

Info

Publication number
CL2008002114A1
CL2008002114A1 CL2008002114A CL2008002114A CL2008002114A1 CL 2008002114 A1 CL2008002114 A1 CL 2008002114A1 CL 2008002114 A CL2008002114 A CL 2008002114A CL 2008002114 A CL2008002114 A CL 2008002114A CL 2008002114 A1 CL2008002114 A1 CL 2008002114A1
Authority
CL
Chile
Prior art keywords
disorder
disease
psychosis
schizophrenia
parkinson
Prior art date
Application number
CL2008002114A
Other languages
English (en)
Inventor
Arto Karjalainen
Gerd Wohlfahrt
Patrik Holm
Belle David Din
Arto Tolvanen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39884455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002114(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of CL2008002114A1 publication Critical patent/CL2008002114A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCIÓN REIVINDICA COMPUESTOS DERIVADOS DE DE 1-(2,3-DIHIDROBENZO[1,41DIOXIN-2-I)METJL)AZACICLOS3SUSHTUIDOS DE FÓRMULA I, DONDE M, X, Z, Y R1 A R4 SE DEFINEN TAL COMO EN EL PLIEGO DE REIVINDICACIONES. LA INVENCIÓN TAMBIÉN APUNTA A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE AL MENOS UNO DE DICHOS COMPUESTOS Y UN PORTADOR, DILUYENTE Y/O EXCIPIENTE FARMACÉUTICAMENTE ACEPTABLE; Y AL USO DE LOS COMPUESTOS EN LA PREPARACIÓN DE UN MEDICAMENTO ÚTIL PARA TRATAR UNA ENFERMEDAD O CONDICIÓN SELECCIONADA DEL GRUPO FORMADO POR UN TRASTORNO MENTAL PROPAGADO POR ESTRÉS, ENFERMEDAD DE PARKINSON, DEPRESIÓN, ESQUIZOFRENIA, TRASTORNO DE DÉFICIT DE ATENCIÓN E HIPERACTIVIDAD, TRASTORNO DE ESTRÉS POST-TRAUMÁTICO, TRASTORNO OBSESIVO COMPULSIVO, SÍNDROME DE TOURETTE, BLEFAROESPASMO U OTRAS DIASTONIAS FOCALES, EPILEPSIA DEL LÓBULO TEMPORAL CON PSICOSIS, UNA PSICOSIS INDUCIDA POR FÁRMACOS, ENFERMEDAD DE HUNTLNGTON, UN TRASTORNO PROVOCADO POR FLUCTUACIÓN DE LOS NIVELES DE HORMONAS SEXUALES, TRASTORNO DE PÁNICO, ENFERMEDAD DE ALZHEIMER O DEFICIENCIA COGNITIVA LEVE.
CL2008002114A 2007-07-20 2008-07-17 Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos-3-sustituidos; composicion farmaceutica; y uso del compuesto para el tratamiento de un trastorno mental propagado por estres, enfermedad de parkinson, esquizofrenia, trastorno de deficit de atencion, trastorno obsesivo compulsivo, psicosis, entre otras. CL2008002114A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95098307P 2007-07-20 2007-07-20

Publications (1)

Publication Number Publication Date
CL2008002114A1 true CL2008002114A1 (es) 2009-04-03

Family

ID=39884455

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002114A CL2008002114A1 (es) 2007-07-20 2008-07-17 Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos-3-sustituidos; composicion farmaceutica; y uso del compuesto para el tratamiento de un trastorno mental propagado por estres, enfermedad de parkinson, esquizofrenia, trastorno de deficit de atencion, trastorno obsesivo compulsivo, psicosis, entre otras.

Country Status (32)

Country Link
US (3) US8492549B2 (es)
EP (1) EP2176252B1 (es)
JP (1) JP5460590B2 (es)
KR (1) KR101535059B1 (es)
CN (1) CN101842369B (es)
AR (1) AR069271A1 (es)
AU (1) AU2008278924B2 (es)
BR (1) BRPI0814529B8 (es)
CA (1) CA2693804C (es)
CL (1) CL2008002114A1 (es)
CO (1) CO6331473A2 (es)
CY (1) CY1115789T1 (es)
DK (1) DK2176252T3 (es)
EA (1) EA017554B1 (es)
ES (1) ES2502215T3 (es)
GE (1) GEP20125538B (es)
HK (1) HK1148530A1 (es)
HR (1) HRP20141156T1 (es)
IL (1) IL202964A (es)
MA (1) MA31521B1 (es)
MY (1) MY153872A (es)
NZ (1) NZ582432A (es)
PE (1) PE20090890A1 (es)
PL (1) PL2176252T3 (es)
PT (1) PT2176252E (es)
RS (1) RS53571B1 (es)
SI (1) SI2176252T1 (es)
TN (1) TN2010000029A1 (es)
TW (1) TWI457122B (es)
UA (1) UA100695C2 (es)
WO (1) WO2009013390A1 (es)
ZA (1) ZA201000314B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
DK2271638T3 (da) 2008-04-29 2011-11-28 Nsab Af Neurosearch Sweden Ab Modulatorer af dopaminneurotransmission
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
MX2010011724A (es) * 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
TW201024282A (en) * 2008-11-20 2010-07-01 Orion Corp New pharmaceutical compounds
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CN105985389B (zh) * 2015-03-06 2019-03-19 北京大学 苯乙醇苷类似物及其合成方法和应用
CA2981041C (en) 2015-03-27 2023-09-05 California Institute Of Technology Asymmetric catalytic decarboxylative alkyl alkylation using low catalyst concentrations and a robust precatalyst
TWI704145B (zh) 2015-06-05 2020-09-11 芬蘭商奧利安公司 新醫藥化合物
EP3426391A4 (en) 2016-03-11 2019-08-28 California Institute of Technology COMPOSITIONS AND METHODS FOR ACYLATING LACTAMEN
JP2019519582A (ja) 2016-06-29 2019-07-11 オリオン コーポレーション ベンゾジオキサン誘導体およびその医薬用途
WO2018169818A1 (en) * 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
EP3480190B1 (en) 2017-11-01 2023-01-04 California Institute of Technology Methods for enantioselective allylic alkylation of esters, lactones, and lactams with unactivated allylic alcohols
GB201801130D0 (en) * 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same
WO2023131640A1 (en) 2022-01-07 2023-07-13 Bayer Aktiengesellschaft α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA
KR20230114646A (ko) * 2022-01-25 2023-08-01 재단법인 한국파스퇴르연구소 벤조다이옥세인 유도체 화합물 및 이의 의약 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2056046A (en) 1933-05-19 1936-09-29 Rhone Poulenc Sa Manufacture of bases derived from benz-dioxane
US3647790A (en) 1969-04-08 1972-03-07 American Home Prod Ouinoxalinyl-oxazolidines and -oxazines
GB1411531A (en) 1972-10-24 1975-10-29 Lafon Labor Amino derivatives of 1,4-benzodioxan
JPS5163193A (ja) * 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US4039676A (en) 1975-06-23 1977-08-02 Ciba-Geigy Corporation 2-piperidinoalkyl-1,4-benzodioxans
US4329348A (en) * 1979-02-26 1982-05-11 Ciba-Geigy Corporation N-Oxacyclic-alkylpiperidines as psychostimulants
HU181575B (en) 1980-10-03 1983-10-28 Richter Gedeon Vegyeszet Process for preparing 3-chloro-propyl-malonic acid ester and cyano-acetic acid ester derivatives
FR2525600A1 (fr) * 1982-04-21 1983-10-28 Bouchara Emile Nouvelles carboxamidoguanidines, leur procede d'obtention et les compositions pharmaceutiques en renfermant
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
DD250930A1 (de) 1986-06-08 1987-10-28 Isis Chemie Zwickau Veb Verfahren zur herstellung neuer tetrahydroisochinolinderivate
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
EP0429535A1 (en) 1988-08-16 1991-06-05 E.I. Du Pont De Nemours And Company Fungicidal benzodioxane amine derivatives
EP0573581A4 (en) 1991-02-26 1994-06-29 Arc 1 Inc Compositions and methods of treatment of sympathetically maintained pain
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
FR2744451B1 (fr) 1996-02-01 1998-04-24 Pf Medicament Nouvelles imidazolidinones, pyrimidinones, et 1,3-diazepin-2 -ones, leur preparation et leurs applications en therapeutique
EP0983239A1 (en) 1997-05-06 2000-03-08 Novo Nordisk A/S Novel heterocyclic compounds
US5902807A (en) 1997-05-12 1999-05-11 Antti Haapalinna Method for the treatment of mental illness in mammals and a composition therefor
NZ504667A (en) 1997-12-04 2003-03-28 Allergan Sales Inc Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors
FI20000480A0 (fi) 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
AU9087301A (en) * 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
IL164203A0 (en) 2002-04-03 2005-12-18 Orion Corp Polycyclic compounds as potent alpah2-adrenoceptorantagonists
WO2004067513A1 (en) 2003-01-27 2004-08-12 Oy Juvantia Pharma Ltd Antagonists for alpha-2 adrenoceptors
TWI457122B (zh) 2007-07-20 2014-10-21 Orion Corp 作為用於治療周邊和中央神經系統疾病之alpha2C拮抗劑的2,3－二氫苯並[1,4]戴奧辛－2－基甲基衍生物
JP5163193B2 (ja) 2008-03-13 2013-03-13 セイコーエプソン株式会社 プリンタシステム及びプリンタシステムにおける制御方法

Also Published As

Publication number Publication date
US8492549B2 (en) 2013-07-23
PE20090890A1 (es) 2009-07-08
US20130281486A1 (en) 2013-10-24
TN2010000029A1 (en) 2011-09-26
KR20100044220A (ko) 2010-04-29
ZA201000314B (en) 2010-10-27
AU2008278924B2 (en) 2013-09-26
US20120035210A9 (en) 2012-02-09
CN101842369B (zh) 2014-01-22
EP2176252A1 (en) 2010-04-21
BRPI0814529B8 (pt) 2021-05-25
UA100695C2 (ru) 2013-01-25
WO2009013390A1 (en) 2009-01-29
DK2176252T3 (en) 2014-12-08
TW200908961A (en) 2009-03-01
JP5460590B2 (ja) 2014-04-02
CN101842369A (zh) 2010-09-22
US8697723B2 (en) 2014-04-15
JP2010534197A (ja) 2010-11-04
PT2176252E (pt) 2014-12-03
ES2502215T3 (es) 2014-10-03
BRPI0814529A2 (pt) 2015-01-27
SI2176252T1 (sl) 2014-12-31
MA31521B1 (fr) 2010-07-01
AU2008278924A1 (en) 2009-01-29
CY1115789T1 (el) 2017-01-25
RS53571B1 (en) 2015-02-27
PL2176252T3 (pl) 2015-04-30
MY153872A (en) 2015-03-31
TWI457122B (zh) 2014-10-21
BRPI0814529B1 (pt) 2019-09-17
EA017554B1 (ru) 2013-01-30
KR101535059B1 (ko) 2015-07-24
EP2176252B1 (en) 2014-09-03
NZ582432A (en) 2012-03-30
US8809536B2 (en) 2014-08-19
AR069271A1 (es) 2010-01-13
EA201070169A1 (ru) 2010-06-30
US20100216836A1 (en) 2010-08-26
IL202964A (en) 2013-12-31
HRP20141156T1 (hr) 2015-01-16
GEP20125538B (en) 2012-05-25
CO6331473A2 (es) 2011-10-20
CA2693804C (en) 2015-11-24
US20140179926A1 (en) 2014-06-26
CA2693804A1 (en) 2009-01-29
HK1148530A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
CL2008002114A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos-3-sustituidos; composicion farmaceutica; y uso del compuesto para el tratamiento de un trastorno mental propagado por estres, enfermedad de parkinson, esquizofrenia, trastorno de deficit de atencion, trastorno obsesivo compulsivo, psicosis, entre otras.
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
ECSP11010885A (es) Heteroarilos sustituidos
CL2008002246A1 (es) Uso de compuestos derivados de benzamida para tratar trastornos del sistema nervioso central seleccionados entre depresion, ansiedad trastornos psicoticos, trastornos neurologicos, epilepsia, trastornos cardiovasculares, diabetes, dislipidemias, entre otros; compuestos derivados de benzamida; composicion farmaceutica; y uso de la composicion.
CL2010001162A1 (es) Compuestos derivados de octahidropirrolo[3,4-c]pirrol disustituidos, moduladores de orexina; composicion farmaceutica que comprende a dichos compuestos; utiles en trastornos del ciclo sueño-vigilia, trastornos metabolicos, trastornos neurologicos, entre otros
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
PA8785401A1 (es) Derivados de bencimidazol
ECSP109904A (es) Compuestos antivirales
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
NZ592571A (en) Aryl piperazine and their use as alpha2c antagonists
GT200600429A (es) Compuestos organicos
ECSP11010804A (es) Compuestos orgánicos
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
BRPI0607309A2 (pt) processos para a preparação de fenilpirazol uréias substituìdas
ECSP12007795A (es) 1h-quinazolin-2,4-dionas y su uso como ligandos del receptor de ampa
CU23836B1 (es) Compuestos 1,3-diona bicíclicos herbicidamente activos
UY29613A1 (es) Compuestos quimicos vi
UY29614A1 (es) Compuestos químicos
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
ECSP099426A (es) Compuestos de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7il para la modulación de la actividad del adrenoreceptor beta2
AR061505A1 (es) Derivados de alfa-amino-amida utiles en el tratamiento de trastornos cognitivos
PA8556901A1 (es) Nuevos derivados de piperazina
CL2013002449A1 (es) Compuestos derivados de heteroaril-bencenosulfonamida, moduladores de nachr alfa 7; composicion farmaceutica; y su uso en la enfermedad de alzheimer, trastorno cognitivo leve, demencia senil, demencia vascular, entre otras.
PE20120324A1 (es) Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.